Stuart Needleman, Aptuit’s president and chief operating officer, said, “The offering is well suited to small and medium-sized Biotechs, CMOs and clinical CROs with limited research capabilities. These companies also benefit from Aptuit’s extensive regulatory experience and compliance with FDA and EMA mandates.”
The biodistribution studies are conducted by scientists in the Preclinical Biosciences group at The Aptuit Center for Drug Discovery & Development in Verona, Italy.
Mr. Needleman added, “The single-site advantage is the springboard for multiple benefits. We offer the flexibility in running studies under both GLP and non-GLP parameters; the possible use of non-human subjects from new facilities; flexibility, rapid response and adaptation during development and real time parallel data for the entire preclinical development study package.”